Hospital De Sao Francisco Xavier — Clinical Trial Site

8 Registered trials

1 Currently recruiting

Organisation

Hospital De Sao Francisco Xavier

Location

Lisbon, Portugal

Identifier

ORG-100041324

Address

Estrada Forte Do Alto Duque, 1449-005, Portugal

Departments

3401: Serviço de Medicina Interna
93149004:Oncologia
Centro de Inovação e Investigação Clínica / Inovation and Clinical Research Centre
Day Hospital
Department of Clinical Hematology
Paediatrics
Serviço de Oncologia
Serviço de Oncologia Médica

Clinical trials at this site (8)

Search interface

EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Ended

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopeni… Ended

2024-513147-90-00 Primary Immune Thrombocytopenia 5 2022-04-26
Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi… Ended

2024-510967-41-00 Metastatic colorectal cancer 5 2018-09-21
A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended

2023-504678-39-00 Heart Failure 4 2024-03-13
A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin for the… Ended

2024-516385-10-00 Acute Bacterial Skin and Skin Structure Infections 4 2023-05-02